Skip to content
value.today

OneMedNet Corp

ONMD
$237 Mmarket cap on Oct 14, 2026
Compare
World rank
#15,648
Revenue
$1 M
For year ending December-2025
Net income
$-3 M
-205.9% margin
SEC filing
Employees
—

OneMedNet Corp in brief

OneMedNet Corp is a listed company in the Diagnostics and Research industry, based in the UK. Its market value was $237 M on 14 October 2026, which makes it the 15,648th largest listed company in the world and the 504th largest in the UK on this site. In the year to December 2025 it had sales of $1 M and a net loss of $3 M. Its largest product and service lines by sales in 2025 were Data Delivery Revenue (92%) and Subscription Revenue (8%). By market, the largest shares of its 2025 sales came from EMEA (51%), Americas (45%) and Asia Pacific (4%). Its shares trade under the symbol ONMD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About OneMedNet Corp

OneMedNet is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data. OneMedNet’s innovative solutions connect healthcare providers and patients satisfying a crucial need within the life sciences field offering direct access to clinical images and the associated contextual patient record. OneMedNet’s innovative technology proved the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OneMedNet’s life science partners case selection protocols and paves the way for Real World Evidence (as defined below).

From the company's annual report filed with the US SEC: read the report

OneMedNet Corp timeline

4 events, 2021–2025
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering as Data Knights Acquisition Corp.
    Final prospectus filed with the SEC on 10 May 2021; shares registered for exchange trading on 5 May 2021. The blank-check company later merged with the business that carries the name today.
  4. 2023
  5. ✎
    Renamed OneMedNet Corp
    Formerly Data Knights Acquisition Corp..
  6. 2025
  7. 💰
    Record revenue of $1 million
    FY2025, the highest of the 4 years on record.

Events of OneMedNet Corp from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
163.6×
Price / book
—
Free cash flow yield
-3.2%
Net margin (TTM)
-586.2%
Operating margin
-711.0%
Return on equity
—
Liabilities / assets
238.1%
Net debt
$-0M
Revenue growth
+112.5%
R&D / revenue
111.8%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $5M—FY21Fiscal year ending Dec 2022: revenue $1M, net income $-30M$1MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-34M$1MFY23Fiscal year ending Dec 2024: revenue $1M, net income $-10M$1MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-3M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M+112.5%$-10M$-3M-205.9%
Dec 2024$1M-37.3%$-10M$-10M-1582.8%
Dec 2023$1M-11.3%$-7M$-34M-3311.8%
Dec 2022$1M—$-8M$-30M-2647.8%
Dec 2021——$-1M$5M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-8M$0M$-8M$-0.06—
Dec 2024$-7M$0M$-7M$-0.36—
Dec 2023$-5M$0M$-5M$-4.65—
Dec 2022$-5M$0M$-5M$-7.66—
Dec 2021$-0M——$0.44—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$1M
Net income, trailing 12 months
$-9M
RevenueNet income
Three months to Sep 2024: revenue $0M, net income $-2M$0MSep ’24Three months to Dec 2024 (from the annual report): revenue $0M, net income $-2M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-2M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $3M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-1M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-3M$1MDec ’25Three months to Mar 2026: revenue $0M, net income $-2M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-2M$0MJun ’26

Latest quarter to Jun 2026: revenue $0M (+81.2% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of OneMedNet Corp with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-10 M
Net income
$-3 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$2 M
Total liabilities
$5 M
Total equity
$-3 M

As of December-2025

Top 13 institutional investors in OneMedNet Corp#

As of Sep 30, 2026
13 institutions held 1.7 M shares (about 2.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 2.8%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 13 largest institutional investors in OneMedNet Corp
#InstitutionShares heldChange (shares)% heldValueFiled
1Savant Capital, LLC1,443,868New2.44%$8 MNov 6, 2026
2Vanguard Capital Management LLC115,221New0.19%$1 MNov 13, 2026
3Geode Capital Management, LLC28,724New0.05%$0 MNov 6, 2026
4State Street Corp14,900New0.03%$0 MNov 12, 2026
5Vanguard Fiduciary Trust Co13,770New0.02%$0 MNov 13, 2026
6BlackRock, Inc.11,878New0.02%$0 MNov 13, 2026
7Discovery Capital Management, LLC / CT11,225New0.02%$0 MNov 16, 2026
8PNC Financial Services Group, Inc.10,333New0.02%$0 MNov 6, 2026
9UBS Group AG2,079New0.00%$0 MNov 10, 2026
10Tower Research Capital LLC (TRC)1,630New0.00%$0 MNov 16, 2026
11Morgan Stanley1,183New0.00%$0 MNov 13, 2026
12Royal Bank Of Canada73New0.00%$0 MNov 16, 2026
13SBI Securities Co., Ltd.15New0.00%$0 MOct 22, 2026

Insider trading at OneMedNet Corp#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$4.2 M
14 purchases, 3 insiders
Sold, 12 months
$103 K
5 sales, 2 insiders
Net, 12 months
$4.1 M
open market only
Insiders on file
11
since
$1.2 M-$144 K$0Dec 2023: bought $8 K (7 trades), sold $0 (0 trades)Dec 23Jan 2024: bought $10 K (16 trades), sold $0 (0 trades)Feb 2024: bought $4 K (5 trades), sold $0 (0 trades)Mar 2024: bought $2 K (3 trades), sold $0 (0 trades)MarApr 2024: bought $65 (1 trades), sold $0 (0 trades)May 2024: bought $1 K (6 trades), sold $0 (0 trades)Jul 2024: bought $4 K (1 trades), sold $0 (0 trades)JulAug 2024: bought $4 K (6 trades), sold $0 (0 trades)Sep 2024: bought $2 K (2 trades), sold $0 (0 trades)Nov 2024: bought $2 K (2 trades), sold $0 (0 trades)NovDec 2024: bought $99 (1 trades), sold $0 (0 trades)Apr 2025: bought $23 K (1 trades), sold $0 (0 trades)Jun 2025: bought $1.2 M (3 trades), sold $0 (0 trades)JunAug 2025: bought $691 K (8 trades), sold $0 (0 trades)Sep 2025: bought $74 K (11 trades), sold $0 (0 trades)Oct 2025: bought $31 K (1 trades), sold $144 K (1 trades)OctNov 2025: bought $0 (0 trades), sold $74 K (1 trades)Feb 2026: bought $500 K (1 trades), sold $0 (0 trades)Apr 2026: bought $1000 K (2 trades), sold $0 (0 trades)AprMay 2026: bought $250 K (1 trades), sold $0 (0 trades)Jun 2026: bought $352 K (6 trades), sold $0 (0 trades)Jul 2026: bought $1000 K (1 trades), sold $0 (0 trades)JulSep 2026: bought $90 K (1 trades), sold $103 K (5 trades)Oct 2026: bought $1000 K (2 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
OneMedNet Corp: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jeffrey YuChief Medical Officer, Director, 10% ownerBuy+45,126$5.540$250 K896,840Form 4
filed Thomas KosasaDirector, 10% ownerBuy+129,758$5.780$750 K1.98 MForm 4
filed Aaron GreenChief Executive Officer, DirectorSell-1,667$6.480$11 K247,971Form 4
filed Aaron GreenChief Executive Officer, DirectorSell-5,000$7.392$37 K249,638Form 4
filed Robert Lawrence GoldenChief Financial Officer, DirectorSell-3,000$6.630$20 K91,291Form 4
filed Robert Lawrence GoldenChief Financial Officer, DirectorSell-3,000$6.300$19 K94,291Form 4
filed Robert Lawrence GoldenChief Financial Officer, DirectorSell-2,500$6.600$17 K97,291Form 4
filed Jeffrey YuChief Medical Officer, Director, 10% ownerBuy+142,857$0.630$90 K8.92 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: OneMedNet Corp#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
133,071
0.3% of shares · 5.77 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-11-09 14:32 UTC, code LUDP, resumed 14:37 UTC
  • 2026-09-28 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 46 shares at $4.37
  • : 2 shares at $4.46
  • : 2,424 shares at $4.38
  • : 3 shares at $4.57
  • : 1,240 shares at $4.66

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

OneMedNet Corp scorecard#

Passes 4 of the 19 checks that could be worked out: strongest in growth (3 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 14, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✗Price to sales below its peers' median163.6×Price to sales 163.6× against Diagnostics and Research's median of 4.5×.
    • ✗Free cash flow yield above 5%-3.2%Free cash flow is -3.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 4
    • ✓Revenue grew in the newest year112.5%Revenue up 112.5% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years5.8%5.8% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median5.8%5.8% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • ✗Earnings per share grew in the newest year-0.06 vs -0.36Diluted EPS -0.06 in fiscal 2025 against -0.36 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-711.0%-711.0% against Diagnostics and Research's median of -2.4% (66 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-711.0%-711.0% in fiscal 2025 against -671.3% in 2022.
  • Financial health1 of 5
    • ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.44 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $0 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-138.1×Operating income -138.1 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-55.90Z-score -55.90 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year58.7%Diluted shares up 58.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from OneMedNet Corp's statements, beside the median of Diagnostics and Research.

OneMedNet Corp: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-711.0%-2.4%
Net margin-205.9%-3.6%
Revenue growth, 3 years a year5.8%3.6%
Revenue growth112.5%6.6%
Free cash flow margin-552.2%4.7%

5of 9on the Piotroski tests of financial strength

  • Net loss of $3 million, the 4th loss-making year in a row.
  • Free cash flow was negative: -$8 million.
  • The share count rose 58.7% in the year.
  • Shareholders' equity is negative: -$3 million.

OneMedNet Corp: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

OneMedNet Corp: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022
Income statement
Revenue1.40.61.0r1.2r
Cost of revenue1.90.91.2r1.5r
Gross profit−0.5−0.3−0.1r−0.4r
Research and development1.51.52.1r1.6r
Selling and marketing1.30.81.1r1.0r
General and administrative6.47.03.5r4.8r
Operating expenses9.29.36.7r7.4r
Operating income−9.7−9.6−6.9r−7.7r
Interest expense and finance costs0.10.10.0r0.4
Other non-operating income (expense)6.9−0.5−27r−23r
Income before tax−2.8−10−34−30r
Income tax0.00.00.00.0r
Income from continuing operations−2.8−10——
Net income including minority interests———0.3
Net income attributable to shareholders−2.8−10−34r−30r
Earnings per share, basic-0.06-0.36-4.65r-7.66
Earnings per share, diluted-0.06-0.36-4.65r-7.66r
Shares, weighted average (basic)45287.3r4.0
Shares, weighted average (diluted)45287.3r4.0
Balance sheet
Cash and cash equivalents0.60.20.0r0.3r
Receivables0.50.20.2r0.0r
Other current assets0.50.40.2r0.1r
Current assets2.13.60.4r0.4r
Property, plant and equipment0.10.10.1r0.1r
Total assets2.23.70.5r1.3r
Accounts payable3.26.0r4.7r1.2r
Debt due within a year1.09.4——
Current liabilities4.81914r26r
Total liabilities5.12014r28r
Retained earnings−104−102−91r−58r
Shareholders' equity−3.0−16−13r−26r
Total liabilities and equity2.23.70.5r1.3r
Shares outstanding52r28244.0r
Cash-flow statement
Depreciation and amortization0.10.10.0r0.0r
Share-based compensation2.00.61.51.9r
Cash from operating activities−7.5−7.0r−4.8r−4.7r
Capital expenditure−0.0−0.1−0.0r−0.1r
Cash from investing activities2.3−2.0−0.0−0.1r
Debt repaid—−0.2——
Cash from financing activities5.69.1r4.6r4.3r
Change in cash0.40.1−0.2r−0.4r
Report10-K10-K10-K10-K/A

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What OneMedNet Corp sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Data Delivery Revenue$1 M92%
  • Subscription Revenue$0 M7.7%

Countries and regions

  • EMEA$1 M51%
  • Americas$1 M45%
  • Asia Pacific$0 M4.1%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at OneMedNet Corp#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 4 · Directors and officers 4 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 2

OneMedNet Corp: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officersShareholder vote8-K
Material agreement8-K
Delisting notice8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of OneMedNet Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$5 MPrivate placement after listing$2 to $10 million2equity, optionsSEC
Mar 2024$5 MPrivate placement after listing$2 to $10 million1debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How OneMedNet Corp compares in Diagnostics and Research

  • Market cap$237 M · higher than 34% of 110
  • Revenue$1 M · higher than 6% of 123
  • Net margin-586.2% · higher than 2% of 112
  • Revenue growth112.5% · higher than 95% of 89
  • Price / sales163.6× · lower than 2% of 85
  • FCF yield-3.2% · higher than 45% of 66

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
OneMedNet Corp🇬🇧$237 M—-586.2%+112.5%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 14, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, SEC annual report, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at OneMedNet Corp? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show OneMedNet Corp's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about OneMedNet Corp? Suggest a correction